Lipitor Generics: Ranbaxy Still In The Driver's Seat As Court Dismisses Mylan Lawsuit Against U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
Two unresolved factual matters stand in the way of Mylan Pharmaceuticals Inc.' s bid to sue U.S. FDA over generic marketing exclusivity for Pfizer's Lipitor, a U.S. federal judge ruled May 2
You may also be interested in...
The Lipitor Files: A Maze Of Plot Twists Leads To A Cliffhanger Worthy Of A "Thriller"
A look at the creation of the mammoth multi-billion dollar brand and its momentous journey though its life cycle.
Mylan Chairman Robert Coury On Lipitor's Future and India/Japan Expansion: An Interview With PharmAsia News
Mylan Inc. CEO Robert J. Coury demonstrated his ability to be a trendsetter when Mylan acquired Matrix Laboratories in 2007 at the highest value - at the time - for an India pharmaceutical company. Though doubted for that move and the next - of buying Merck KGaA's generics business for $6.8 billion, Coury now boasts of establishing a global generics footprint with a one-of-a-kind vertically integrated platform to build maximum operational efficiencies.
Mylan Chairman Robert Coury On Lipitor's Future and India/Japan Expansion: An Interview With PharmAsia News
Mylan Inc. CEO Robert J. Coury demonstrated his ability to be a trendsetter when Mylan acquired Matrix Laboratories in 2007 at the highest value - at the time - for an India pharmaceutical company. Though doubted for that move and the next - of buying Merck KGaA's generics business for $6.8 billion, Coury now boasts of establishing a global generics footprint with a one-of-a-kind vertically integrated platform to build maximum operational efficiencies.